Nicholas Chinskey, MD
Ophthalmology · St Louis, MONPI 1174847941
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 38.6% of the total. That places this record below the midpoint for ophthalmology clinicians in MO, where the typical reported total is $1,365.
Across 37 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$244
- Apellis Pharmaceuticals, Inc.$136
- AbbVie$67
- Sandoz$57
- ANI Pharmaceuticals, Inc.$49
- Genentech USA, Inc.$32
- plus $46 from 2 others
Across 73 payments — averaging $4097.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Apellis Pharmaceuticals, Inc.$214K
- Genentech, Inc.$76K
- F. Hoffmann-la Roche AG$9K
What the payments were for
- Food & beverage$632100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 15 | $244 |
| Apellis Pharmaceuticals, Inc. | 8 | $136 |
| AbbVie | 4 | $67 |
| Sandoz | 2 | $57 |
| ANI Pharmaceuticals, Inc. | 3 | $49 |
| Genentech USA, Inc. | 2 | $32 |
| Bausch & Lomb Americas Inc. | 2 | $31 |
| Astellas Pharma US Inc | 1 | $15 |
How this compares
$632 in reported general payments places this provider in the 35th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 130 | $6,265 |
| ProlensaBromfenac Sodium | 12 | $4,075 |
| Atropine Sulfate | 28 | $1,013 |
| Latanoprost | 67 | $942 |
| Ketorolac Tromethamine | 13 | $435 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 26 | $402 |
| Timolol Maleate | 31 | $376 |
| Dorzolamide Hcl | 13 | $257 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 34 | $246 |
| Cyclopentolate Hcl | 14 | $243 |
| Ofloxacin | 25 | $236 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in St Louis
- Levent AkdumanSt Louis$47K
- Steven SilversteinKansas City$872K
- Ranjan MalhotraSaint Louis$809K
- Nancy HolekampChesterfield$768K
- Jay PeposeChesterfield$516K
- Gregg BerdySaint Louis$360K
- Joseph GiraDes Peres$174K
- Joseph TauberKansas City$174K
- Jella AnColumbia$166K
- Shachar TauberSpringfield$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.